Parkinson Disease Clinical Trials
Parkinson Disease Trials at a Glance
486 actively recruiting trials for parkinson disease are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Not Applicable with 256 trials, with the heaviest enrollment activity in Boston, New York, and Milan. Lead sponsors running parkinson disease studies include University of Minnesota, National Taiwan University Hospital, and Radboud University Medical Center.
Browse parkinson disease trials by phase
Top cities for parkinson disease trials
Treatments under study
Understanding Parkinson Disease Clinical Trials
Levodopa, the most effective Parkinson disease medication available today, was brought to clinical practice through trials conducted in the late 1960s and remains the gold standard more than five decades later. Since then, clinical trials have delivered additional tools including dopamine agonists, MAO-B inhibitors, COMT inhibitors, and deep brain stimulation (DBS). Current trials are pursuing what has eluded researchers so far — therapies that can slow or stop the underlying neurodegeneration rather than just managing symptoms, including gene therapies, alpha-synuclein-targeting antibodies, and GLP-1 receptor agonists that showed surprising neuroprotective potential in recent studies.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Parkinson Disease clinical trials
Yes. Most Parkinson disease trials allow participants to continue their existing medications, including levodopa. Some trials may require that you be on a stable medication dose for a certain period before enrolling. Trials for newly diagnosed patients sometimes specifically enroll people who have not yet started levodopa, but these are clearly identified in the eligibility criteria.
A disease-modifying trial tests whether a treatment can slow or stop the underlying loss of brain cells, which would change the long-term course of the disease. A symptomatic trial tests whether a treatment can improve day-to-day symptoms without necessarily affecting the disease process itself. Both types are important, but disease-modifying trials are considered the most urgent unmet need.
Increasingly, yes. Some trials, especially observational studies and certain digital health trials, allow remote participation using wearable sensors, smartphone apps, and telemedicine visits. However, trials testing new drugs or procedures typically require some in-person visits for safety monitoring. Ask about decentralized or hybrid trial options.
Many Parkinson trials do include a placebo group, but participants continue receiving their regular Parkinson medications alongside the study treatment or placebo. This means you are never left without symptomatic treatment. Surgical trials may use sham procedures, which are discussed thoroughly during the consent process.
A DATscan is a brain imaging test that measures dopamine transporter levels, helping confirm the diagnosis of Parkinson disease. Many trials require a DATscan during screening to verify that participants have the characteristic dopamine deficiency. The scan involves a small injection of a radioactive tracer followed by a SPECT camera image and is generally well tolerated.
Showing 1–20 of 486 trials